Suppr超能文献

经导管介入治疗左心瓣膜性心脏病合并心源性休克:欧洲经皮心血管介入学会(EAPCI)与急性心血管护理协会(ACVC)和 ESC 心血管外科学工作组合作的共识声明。

Transcatheter interventions for left-sided valvular heart disease complicated by cardiogenic shock: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the Association for Acute Cardiovascular Care (ACVC) and the ESC Working Group on Cardiovascular Surgery.

机构信息

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.

Heart Valves Unit, Georges Pompidou European Hospital, Université Paris Cité, INSERM, Paris, France.

出版信息

EuroIntervention. 2023 Oct 23;19(8):634-651. doi: 10.4244/EIJ-D-23-00473.

Abstract

Valvular heart disease (VHD) is one of the most frequent causes of heart failure (HF) and is associated with poor prognosis, particularly among patients with conservative management. The development and improvement of catheter-based VHD interventions have broadened the indications for transcatheter valve interventions from inoperable/high-risk patients to younger/lower-risk patients. Cardiogenic shock (CS) associated with severe VHD is a clinical condition with a very high risk of mortality for which surgical treatment is often deemed a prohibitive risk. Transcatheter valve interventions might be a promising alternative in this setting given that they are less invasive. However, supportive scientific evidence is scarce and often limited to small case series. Current guidelines on VHD do not contain specific recommendations on how to manage patients with both VHD and CS. The purpose of this clinical consensus statement, developed by a group of international experts invited by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Scientific Documents and Initiatives Committee, is to perform a review of the available scientific evidence on the management of CS associated with left-sided VHD and to provide a rationale and practical approach for the application of transcatheter valve interventions in this specific clinical setting.

摘要

瓣膜性心脏病(VHD)是心力衰竭(HF)最常见的原因之一,与预后不良有关,特别是在保守治疗的患者中。基于导管的 VHD 介入技术的发展和改进拓宽了经导管瓣膜介入治疗的适应证,从不能手术/高危患者扩大到年轻/低危患者。与严重 VHD 相关的心源性休克(CS)是一种临床状况,死亡率极高,手术治疗通常被认为风险过高。鉴于经导管瓣膜介入治疗的创伤较小,它可能是一种很有前途的替代治疗方法。然而,支持性的科学证据很少,而且往往仅限于小病例系列。目前的 VHD 指南中没有关于如何治疗同时患有 VHD 和 CS 的患者的具体建议。本临床共识声明由欧洲经皮心血管介入协会(EAPCI)科学文件和倡议委员会邀请的一组国际专家制定,旨在对与左侧 VHD 相关的 CS 的管理的现有科学证据进行回顾,并为经导管瓣膜介入治疗在这一特定临床环境中的应用提供合理的依据和实用方法。

相似文献

引用本文的文献

1
[The TAVI heart team].[经导管主动脉瓣植入术心脏团队]
Herz. 2025 Sep 9. doi: 10.1007/s00059-025-05331-z.
5
Left Atrial Veno-Arterial Extracorporeal Membrane Oxygenation In Valvular Cardiogenic Shock.左心房静脉 - 动脉体外膜肺氧合治疗瓣膜性心源性休克
J Soc Cardiovasc Angiogr Interv. 2025 May 1;4(5):102615. doi: 10.1016/j.jscai.2025.102615. eCollection 2025 May.
8
Acute Decompensated Valvular Disease in the Intensive Care Unit.重症监护病房中的急性失代偿性瓣膜病
JACC Adv. 2024 Dec 26;3(12):101402. doi: 10.1016/j.jacadv.2024.101402. eCollection 2024 Dec.

本文引用的文献

5
Impact of Procedure Volume on the Outcomes of Surgical Aortic Valve Replacement.手术主动脉瓣置换术的术式量效关系。
Thorac Cardiovasc Surg. 2024 Apr;72(3):173-180. doi: 10.1055/s-0042-1754352. Epub 2022 Aug 2.
6
Acute valvular emergencies.急性瓣膜紧急情况。
Eur Heart J Acute Cardiovasc Care. 2022 Aug 9;11(8):653-665. doi: 10.1093/ehjacc/zuac086.
7
Mechanical Circulatory Support Options in Patients With Aortic Valve Pathology.主动脉瓣病变患者的机械循环支持选择。
J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt B):3318-3326. doi: 10.1053/j.jvca.2022.04.010. Epub 2022 Apr 14.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验